18F-FDG PET in parkinsonism: differential diagnosis and evaluation of cognitive impairment

PT Meyer, L Frings, G Rücker… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Accurate differential diagnosis of parkinsonism is of paramount therapeutic and prognostic
importance. In addition, with the development of invasive therapies and novel disease …

[HTML][HTML] Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease …

P Odin, KR Chaudhuri, JT Slevin, J Volkmann… - Parkinsonism & Related …, 2015 - Elsevier
Navigate PD was an educational program established to supplement existing guidelines
and provide recommendations on the management of Parkinson's disease (PD) refractory to …

Breaking barriers: exploring mechanisms behind opening the blood–brain barrier

MEM Stamp, M Halwes, D Nisbet, DJ Collins - Fluids and Barriers of the …, 2023 - Springer
The blood–brain barrier (BBB) is a selectively permeable membrane that separates the
bloodstream from the brain. While useful for protecting neural tissue from harmful …

Levodopa–carbidopa intestinal gel in patients with Parkinson's disease: a systematic review

K Wirdefeldt, P Odin, D Nyholm - CNS drugs, 2016 - Springer
Background Levodopa–carbidopa intestinal gel (LCIG) is available in several countries for
the treatment of advanced levodopa-responsive Parkinson's disease (PD) with severe motor …

Algorithms for the treatment of motor problems in Parkinson's disease

E Dietrichs, P Odin - Acta Neurologica Scandinavica, 2017 - Wiley Online Library
Several different strategies are effective for medical treatment of motor problems in
Parkinson's disease (PD). Many guidelines and evidence‐based reviews are available, but …

Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3 …

AJ Espay, F Stocchi, R Pahwa, A Albanese… - The Lancet …, 2024 - thelancet.com
Background Conventional oral levodopa therapy for the treatment of Parkinson's disease
can be associated with variations in plasma concentrations. Levodopa infusion strategies …

Update on the management of Parkinson's disease for general neurologists

Z Pirtošek, O Bajenaru, N Kovács, I Milanov… - Parkinson's …, 2020 - Wiley Online Library
Management of Parkinson's disease (PD) is complicated due to its progressive nature, the
individual patient heterogeneity, and the wide range of signs, symptoms, and daily activities …

Interfacing electrogenic cells with 3D nanoelectrodes: position, shape, and size matter

F Santoro, S Dasgupta, J Schnitker, T Auth… - ACS …, 2014 - ACS Publications
An in-depth understanding of the interface between cells and nanostructures is one of the
key challenges for coupling electrically excitable cells and electronic devices. Recently …

Treatment of advanced Parkinson's disease

JC Giugni, MS Okun - Current opinion in neurology, 2014 - journals.lww.com
The optimization of levodopa is, in most cases, the most powerful therapeutic option
available; however, medication optimization requires an advanced understanding of …

E ffect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced P arkinson's disease patients

A Antonini, VSC Fung, JT Boyd, JT Slevin… - Movement …, 2016 - Wiley Online Library
Objective The purpose of this study was to assess the effect of levodopa‐carbidopa
intestinal gel (carbidopa‐levodopa enteral suspension) in advanced Parkinson's disease …